NanoKTN member wins SET For Britain award
Medal awarded to ThaoNguyen Nguyen for Porphyrin-DNA poster
ThaoNguyen Nguyen was awarded the medal for her poster that looked at the use of Porphyrin-DNA as a scaffold for nanoarchitectures. The poster was judged the best chemistry presentation.
ThaoNguyen’s research focuses on the use of DNA as architecture for Porphyrin chromophore arrays (natural molecules found in heme or chlorophyll) for applications in future nanochips and potentially in photodynamic therapy for cancer treatment. The results show that DNA has great potential for the transformation from being a building block of life to being a building block for nanotechnology.
SET for Britain aims to encourage, support and promote Britain's early-stage and early-career research scientists, engineers and technologists to ensure continued progress in the development of UK research and r&d, and ultimately the future of UK business. The awards give early-career scientists the opportunity to communicate state-of-the-art science to Members of Parliament and scientific peers.
ThaoNguyen’s poster also won the EPSRC Award for Young Scientist at the UK Nano & Emerging Technologies Forum last year, hosted by the Nano Knowledge Transfer Network (NanoKTN) and UK Trade & Investment (UKTI). Being a NanoKTN member and winning the EPSRC Award contributed towards ThaoNguyen’s success at SET for Britain and has had a great impact on promoting her research.
‘Winning the Roscoe Medal and the EPSRC Award has given me opportunities to communicate my research to a broader audience, one that I would not normally expect to meet,’ she said.
‘Embedding an awareness within the next generation of current research will help to strengthen business and hopefully create further connections between academia and industry.’
Established by the Technology Strategy Board, the NanoKTN is managed by Centre for Process Innovation, a technology development and consulting company.
You may also like
Drug Delivery
Bio-Sourcing and Zerion Pharma secure Eurostars funding to develop HER2 oral monoclonal antibody
The pair have been awarded a €1.3m Eurostars grant to develop an oral formulation of the anti-HER2 monoclonal antibody trastuzumab for breast cancer, combining Bio-Sourcing’s BioMilk platform with Zerion’s Dispersome technology to advance the candidate through preclinical development
Research & Development
FairJourney Bio launches cryo-EM services to support antibody discovery and biologics design
The new offering at the company's San Diego laboratories provides high-resolution structural insights to accelerate antibody discovery, selection and optimisation across the biologics R&D pipeline
Research & Development
Studies on HIV and TB reveal tradeoffs for both viruses and immune system in race to survive
Research teams have identified mechanisms by which HIV can evade lenacapavir, at the cost of the virus's reproduction and how the immune system can use bacteria to protect against infection — until TB evolved to take advantage
Research & Development
Enara Bio expands Boehringer Ingelheim partnership as DARKFOX programme moves toward the clinic
Enara Bio has entered 2026 with renewed momentum after Boehringer Ingelheim licensed additional Dark Antigen targets under their oncology collaboration. The company is also continuing to expand its EDAPT discovery platform
Research & Development
Early stage clinical trials highlight the convergence of novel therapeutics and enabling technologies
Early stage clinical development is increasingly being shaped by advances in drug discovery and the technologies and manufacturing strategies that enable the safe, precise and scalable delivery of new therapies